Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 101-110 of 290 for lung cancer

Edit search filters
  1. A Global Study To Assess The Effects Of Durvalumab + Domvanalimab Following Concurrent Chemoradiation In Participants With Stage III Unresectable NSCLC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study To Evaluate The Effect Of Canakinumab Or Pembrolizumab Given As Monotherapy Or In Combination As Neo-adjuvant Treatment For Subjects With Early Stages NSCLC

    Scottsdale/Phoenix, AZ

  3. Neoadjuvant Pembrolizumab

    Rochester, MN

  4. Personalized Smoking Cessation Tool Based on Patient Lung CT Image

    Rochester, MN

  5. Stereotactic Body Radiation Therapy With Immunotherapy For The Treatment Of Mesothelioma

    Rochester, MN

  6. Study Of Datopotamab Deruxtecan (Dato-DXd) In Combination With Durvalumab And Carboplatin For First-Line Treatment Of Patients With Advanced NSCLC Without Actionable Genomic Alterations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. JSI-1187-01 Monotherapy And In Combination With Dabrafenib For Advanced Solid Tumors With MAPK Pathway Mutations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Atezolizumab, Pemetrexed Disodium, Cisplatin, And Surgery With Or Without Radiation Therapy In Treating Patients With Stage I-III Pleural Malignant Mesothelioma

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Atezolizumab Immunotherapy In Patients With Advanced NSCLC (AJCC 7th Edition)

    Scottsdale/Phoenix, AZ

  10. Pembrolizumab With Or Without Anetumab Ravtansine In Treating Patients With Mesothelin-Positive Pleural Mesothelioma

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer